Cas:1000932-34-2 5-methyl-3-pyrrolidin-2-yl-1,2-oxazole manufacturer & supplier

Chemical Name:5-methyl-3-pyrrolidin-2-yl-1,2-oxazole

CAS.NO:1000932-34-2

Synonyms:5-methyl-3-pyrrolidin-2-ylisoxazole

Molecular Formula:C₈H₁₂N₂O

Molecular Weight:152.19400

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:38.06000

Exact Mass:152.09500

LogP:1.73630

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:UN 2811 6.1 / PGIII

Packing Group:

Contact us for information like 5-methyl-3-pyrrolidin-2-ylisoxazole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-methyl-3-pyrrolidin-2-ylisoxazole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-methyl-3-pyrrolidin-2-ylisoxazole Use and application,5-methyl-3-pyrrolidin-2-ylisoxazole technical grade,usp/ep/jp grade.

Related News: In a statement to Fierce Medtech, Innova said it has completed some corrective actions, while others are still underway, and that the U.S. recall was launched to reclaim tests distributed to employees, clinical studies and to customers for early evaluation. The company said it plans to seek an emergency use authorization and comply with all FDA requirements. 5-methyl-3-pyrrolidin-2-yl-1,2-oxazole manufacturer Adding Darzalex to Bristol Myers Squibb’s Revlimid and steroid dexamethasone (Rd) could slash the risk of death by 32% in newly diagnosed multiple myeloma patients ineligible to receive stem cell transplants, J&J reported at the European Hematology Association’s virtual congress. 5-methyl-3-pyrrolidin-2-yl-1,2-oxazole supplier In the context of increasingly tight global productive capacity cooperation in the pharmaceutical industry, some multinational pharmaceutical companies have chosen to abandon their original full industrial chain model and shift their focus to market operations. R & D, clinical, and production links reduce costs through outsourcing. Patented APIs came into being. 5-methyl-3-pyrrolidin-2-yl-1,2-oxazole vendor In a statement to Fierce Medtech, Innova said it has completed some corrective actions, while others are still underway, and that the U.S. recall was launched to reclaim tests distributed to employees, clinical studies and to customers for early evaluation. The company said it plans to seek an emergency use authorization and comply with all FDA requirements. 5-methyl-3-pyrrolidin-2-yl-1,2-oxazole factory Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML).